Dollar Falls as Oil Eases, Yen Jumps on Intervention Signals 
Australia Unemployment Hits Five-Year High Despite Strong Jobs Growth 
Dollar Holds Near Two-Month High as Yen Approaches 160 
Japanese Yen Rebounds as Trump Flags Currency Weakness 
Fed Unveils Stablecoin Rules Under GENIUS Act 
Asian Stocks Fall as Surging Bond Yields Rattle Markets 
Fed Unveils Stablecoin Rules Under GENIUS Act 
Oil Prices Ease as Iran Tensions Clash With Diplomacy Hopes 
Oil Prices Fall on U.S.-Iran Hormuz Deal Hopes 
Japan Private-Sector Growth Slows as Domestic Demand Weakens 
Wall Street Ends Flat as Oil, Treasury Yields and Fed Jitters Rattle Markets 
Canadian Dollar Faces Pressure as Fed-BoC Policy Gap Widens 
US 10-Year Treasury Yield at 6% Emerges as New Market Risk Threshold 
U.S. Dollar Hits Two-Month High as Oil, Treasury Yields Surge 
Oil Prices Jump 3% as Houthi Attack Revives Supply Fears 
Gold Prices Fall as Treasury Yields Rise on Fed Rate Hike Bets 
Asian Currencies Mixed as Dollar Holds Near Two-Month High 
Add as a preferred source on Google
Swiss pharmaceutical leader Roche confirmed it has no plans for layoffs, emphasizing a healthy business outlook. CEO Thomas Schinecker highlighted steady research funding and workforce stability despite global economic challenges in Europe and China, as well as setbacks in cancer drug development.
Roche Maintains Workforce Stability Amid Market Challenges
Roche, a Swiss pharmaceutical corporation, does not intend to reduce its workforce, and the company's business is doing well. According to a statement made by CEO Thomas Schinecker, which was published in a Swiss publication on Sunday, Investing.com shares.
The stock price of Roche has dropped significantly below the highs it reached in April 2022, and the CEO was questioned about the company's plans for personnel in light of recent setbacks in the company's efforts to produce pharmaceuticals to cure a variety of illnesses, including cancer.
Schinecker responded to a question about whether or not the company was preparing to lay off employees by saying, "The number of workers is constant to slightly increasing," during an interview with the NZZ am Sonntag.
Research and Development Budgets Remain Steady
"I can say with certainty that we have a very healthy business. And we don't have a growth problem either," he remarked, pointing out that Roche's funding for research and development was consistent and not expanding. He also included this information in his statement.
When Schinecker was asked when Roche's intended anti-obesity medicine would be available for purchase, he responded that it may be as early as 2029 or perhaps earlier.
European Economic Struggles Create Headwinds for Recovery
While discussing the forecast for the coming year in a broader sense, particularly in light of the recent difficulties that the German economy has been experiencing, the CEO of Roche stated that Europe still faced problems.
"There's some economic growth in the United States, but things are more difficult in China at the moment," he explained to reporters. "And in Europe it will take some time before we get out of this."
